Polygenic effect on accelerated tau pathology accumulation in Alzheimer’s disease: implications for patient selection in clinical trials
View ORCID ProfileAnna Rubinski, Simon Frerich, Rainer Malik, Nicolai Franzmeier, Alfredo Ramirez, Martin Dichgans, Michael Ewers, Alzheimer’s Disease Neuroimaging Initiative (ADNI)
doi: https://doi.org/10.1101/2021.11.02.21265788
Anna Rubinski
1Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany
Simon Frerich
1Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany
Rainer Malik
1Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany
Nicolai Franzmeier
1Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany
Alfredo Ramirez
2Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
3Department of Neurodegenerative diseases and Geriatric Psychiatry, University Hospital Bonn, Medical Faculty, Bonn, Germany
4Department of Psychiatry & Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, San Antonio, TX, USA
5German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
6Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne, Cologne, Germany
Martin Dichgans
1Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany
7German Center of Neurodegenerative Diseases (DZNE), Munich
8SyNergy Cluster Munich
Michael Ewers
1Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany
8SyNergy Cluster Munich
Data Availability
The data that used in this study were obtained from the Alzheimer's disease Neuroimaging Initiative (ADNI) and are available from the ADNI database (adni.loni.usc.edu) upon registration and compliance with the data usage agreement.
Posted November 02, 2021.
Polygenic effect on accelerated tau pathology accumulation in Alzheimer’s disease: implications for patient selection in clinical trials
Anna Rubinski, Simon Frerich, Rainer Malik, Nicolai Franzmeier, Alfredo Ramirez, Martin Dichgans, Michael Ewers, Alzheimer’s Disease Neuroimaging Initiative (ADNI)
medRxiv 2021.11.02.21265788; doi: https://doi.org/10.1101/2021.11.02.21265788
Polygenic effect on accelerated tau pathology accumulation in Alzheimer’s disease: implications for patient selection in clinical trials
Anna Rubinski, Simon Frerich, Rainer Malik, Nicolai Franzmeier, Alfredo Ramirez, Martin Dichgans, Michael Ewers, Alzheimer’s Disease Neuroimaging Initiative (ADNI)
medRxiv 2021.11.02.21265788; doi: https://doi.org/10.1101/2021.11.02.21265788
Subject Area
Subject Areas
- Addiction Medicine (322)
- Allergy and Immunology (625)
- Anesthesia (162)
- Cardiovascular Medicine (2340)
- Dermatology (205)
- Emergency Medicine (375)
- Epidemiology (11708)
- Forensic Medicine (10)
- Gastroenterology (694)
- Genetic and Genomic Medicine (3694)
- Geriatric Medicine (347)
- Health Economics (632)
- Health Informatics (2375)
- Health Policy (927)
- Hematology (340)
- HIV/AIDS (773)
- Medical Education (364)
- Medical Ethics (104)
- Nephrology (396)
- Neurology (3456)
- Nursing (195)
- Nutrition (520)
- Oncology (1805)
- Ophthalmology (533)
- Orthopedics (218)
- Otolaryngology (286)
- Pain Medicine (231)
- Palliative Medicine (66)
- Pathology (444)
- Pediatrics (1021)
- Primary Care Research (416)
- Public and Global Health (6094)
- Radiology and Imaging (1263)
- Respiratory Medicine (822)
- Rheumatology (375)
- Sports Medicine (320)
- Surgery (397)
- Toxicology (50)
- Transplantation (171)
- Urology (145)